| Ytd | -23.54% | |
| 1y | 39.21% |
| Open | 26.17 | Prev Close | 26.47 | Low | 25.99 | High | 26.17 | Mkt Cap | 420.69M |
| Vol | 8.02K | Avg Vol | 204.29K | EPS | -0.11 | P/E | -240.64 | Forward P/E | -2.12 |
| Beta | 1.08 | Short Ratio | 0.41 | Inst. Own | 18.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 26.47 | 200-d Avg | 29.23 | 1yr Est | 35.50 |
ASMB News
Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and rais
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy duri
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences fo
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maint
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS
US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe
Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat
Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics
"We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1
Assembly Biosciences NASDAQ: ASMB Chief Medical Officer Anuj Gaggar outlined the company's virology
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Tran
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: AS
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Conse
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the ana
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent ge
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has been given a consensus rating of "Mo
Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payme
Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks C
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, i
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report)'s stock price passed above its 200-day m
Monday saw 196 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Stocks Which Set New 52-Week Low Yesterday, October 23rd
Stocks Which Set New 52-Week Low Yesterday, October 11th
Stocks Which Set New 52-Week Low Yesterday, October 10th
Stocks Which Set New 52-Week Low Yesterday, October 9th
Stocks Which Set New 52-Week Low Friday, October 5th